Summary
Global Markets Direct’s, ‘Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016’, provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL)
- The report reviews pipeline therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Relapsed Chronic Lymphocytic Leukemia (CLL) therapeutics and enlists all their major and minor projects
- The report assesses Relapsed Chronic Lymphocytic Leukemia (CLL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
4SC AG
AbbVie Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Cyclacel Pharmaceuticals, Inc.
Emergent BioSolutions Inc.
F. Hoffmann-La Roche Ltd.
Hutchison MediPharma Limited
ImmunoGen, Inc.
Immunomedics, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Innate Pharma S.A.
Juno Therapeutics Inc.
Karyopharm Therapeutics, Inc.
Les Laboratoires Servier SAS
LFB S.A.
Lymphocyte Activation Technologies, S.A.
Millennium Pharmaceuticals, Inc.
MorphoSys AG
Novartis AG
Oncternal Therapeutics, Inc.
Ono Pharmaceutical Co., Ltd.
Portola Pharmaceuticals, Inc.
Sanofi
TG Therapeutics, Inc.
Threshold Pharmaceuticals, Inc.
Tragara Pharmaceuticals, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Relapsed Chronic Lymphocytic Leukemia (CLL) Overview 8
Therapeutics Development 9
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview 9
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 10
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 13
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 17
Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 20
Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 21
4SC AG 21
AbbVie Inc. 22
Astellas Pharma Inc. 23
Astex Pharmaceuticals, Inc. 24
AstraZeneca Plc 25
Boehringer Ingelheim GmbH 26
Bristol-Myers Squibb Company 27
Celgene Corporation 28
Cyclacel Pharmaceuticals, Inc. 29
Emergent BioSolutions Inc. 30
F. Hoffmann-La Roche Ltd. 31
Hutchison MediPharma Limited 32
ImmunoGen, Inc. 33
Immunomedics, Inc. 34
Incyte Corporation 35
Infinity Pharmaceuticals, Inc. 36
Innate Pharma S.A. 37
Juno Therapeutics Inc. 38
Karyopharm Therapeutics, Inc. 39
Les Laboratoires Servier SAS 40
LFB S.A. 41
Lymphocyte Activation Technologies, S.A. 42
Millennium Pharmaceuticals, Inc. 43
MorphoSys AG 44
Novartis AG 45
Oncternal Therapeutics, Inc. 46
Ono Pharmaceutical Co., Ltd. 47
Portola Pharmaceuticals, Inc. 48
Sanofi 49
TG Therapeutics, Inc. 50
Threshold Pharmaceuticals, Inc. 51
Tragara Pharmaceuticals, Inc. 52
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 53
Assessment by Monotherapy Products 53
Assessment by Combination Products 54
Assessment by Target 55
Assessment by Mechanism of Action 58
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
(INCB-039110 + INCB-040093) - Drug Profile 65
4SC-202 - Drug Profile 66
acalabrutinib - Drug Profile 68
ACP-319 - Drug Profile 71
afuresertib hydrochloride - Drug Profile 72
AGS-67E - Drug Profile 75
AT-7519 - Drug Profile 77
AZD-6738 - Drug Profile 80
BI-836826 - Drug Profile 82
BMS-986016 - Drug Profile 83
buparlisib hydrochloride - Drug Profile 84
CC-122 - Drug Profile 88
Cellular Immunotherapy for Chronic Lymphocytic Leukemia - Drug Profile 90
Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile 91
cerdulatinib - Drug Profile 92
duvelisib - Drug Profile 94
evofosfamide - Drug Profile 97
HMPL-523 - Drug Profile 104
IMGN-529 - Drug Profile 105
IMMU-114 - Drug Profile 107
JCAR-014 - Drug Profile 108
JCAR-015 - Drug Profile 109
lirilumab - Drug Profile 111
monalizumab - Drug Profile 113
MOR-208 - Drug Profile 115
nivolumab - Drug Profile 117
obinutuzumab - Drug Profile 125
otlertuzumab - Drug Profile 129
pilaralisib - Drug Profile 131
PNK-007 - Drug Profile 134
S-055746 - Drug Profile 135
sapacitabine - Drug Profile 136
selinexor - Drug Profile 138
spebrutinib besylate - Drug Profile 144
TAK-659 - Drug Profile 146
TG-02 - Drug Profile 147
TGR-1202 - Drug Profile 150
tisagenlecleucel-T - Drug Profile 153
ublituximab - Drug Profile 156
UC-961 - Drug Profile 159
ulocuplumab - Drug Profile 160
urelumab - Drug Profile 162
venetoclax - Drug Profile 164
Relapsed Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 168
Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 260
Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 261
Relapsed Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 262
Featured News & Press Releases 262
Appendix 270
Methodology 270
Coverage 270
Secondary Research 270
Primary Research 270
Expert Panel Validation 270
Contact Us 270
Disclaimer 271
List of Tables
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H1 2016 12
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Number of Products under Development by Companies, H1 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Development, H1 2016 19
Products under Development by Companies, H1 2016 20
Products under Development by Companies, H1 2016 (Contd..1) 21
Products under Development by Companies, H1 2016 (Contd..2) 22
Products under Investigation by Universities/Institutes, H1 2016 23
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2016 24
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H1 2016 25
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H1 2016 26
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 27
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H1 2016 28
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 29
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H1 2016 30
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H1 2016 31
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 32
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Emergent BioSolutions Inc., H1 2016 33
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 34
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H1 2016 35
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H1 2016 36
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H1 2016 37
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H1 2016 38
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016 39
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma S.A., H1 2016 40
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H1 2016 41
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 42
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H1 2016 43
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H1 2016 44
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies, S.A., H1 2016 45
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 46
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H1 2016 47
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H1 2016 48
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics, Inc., H1 2016 49
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 50
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H1 2016 51
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H1 2016 52
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics, Inc., H1 2016 53
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 54
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H1 2016 55
Assessment by Monotherapy Products, H1 2016 56
Assessment by Combination Products, H1 2016 57
Number of Products by Stage and Target, H1 2016 59
Number of Products by Stage and Mechanism of Action, H1 2016 62
Number of Products by Stage and Route of Administration, H1 2016 65
Number of Products by Stage and Molecule Type, H1 2016 67
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H1 2016 171
Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2016 263
Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2016 264
List of Figures
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H1 2016 12
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Assessment by Monotherapy Products, H1 2016 56
Number of Products by Top 10 Targets, H1 2016 58
Number of Products by Stage and Top 10 Targets, H1 2016 58
Number of Products by Top 10 Mechanism of Actions, H1 2016 61
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 61
Number of Products by Routes of Administration, H1 2016 64
Number of Products by Stage and Routes of Administration, H1 2016 64
Number of Products by Molecule Types, H1 2016 66
Number of Products by Stage and Molecule Types, H1 2016 66
